Member Info for RayPointer

Knowlesi, you would get a lot more respect from people if you just admit it when you have made a mistake.

Sure, youse lot are a load of rampers.
I'm away to tell Father Tommy all about youse.

MQL4 if you are referring to the language, Ruck.

Sorry, trying to program at the same time. I'd hate to know what rubbish I have coded this afternoon.

Father Ted is my favourite.

But who will play Father Jack?

https://www.youtube.com/watch?v=Zbf30DwlEUU

Yes Ruck
The thought occurred to me as well.

Keep talking.
The share price has gone up. The market is listening LOL

I've always like the BionTech collaboration since it probably came about from a scientist talking to a scientist.
You look at some of the deals (for instance the Genentech AI deals) and you wonder if they are buying because something is in fashion. They feel they are missing out if they don't invest in a certain area.

OK got it.

So, upfront payment, followed by milestone payments.
The BionTech deal (when it comes) being the first of many hopefully

I just wouldn't want Lindy to have to do the bidding of a bunch of corporate executives.

Can we be clear?

Does "develop and license" in this context mean develop a drug until it is approved and then license?

My preference has always been an outright purchase of Scancell.

One where Scancell continues as an entity with Lindy's science being fully funded and funding trials is not a problem.

One where Lindy remains a free spirit to go where her science takes her.

When inan goes off on one I can't help bursting out laughing.
It makes me think of my dear departed Irish mother-in-law (sorry inan)

So come on fellas, lighten up.

Inan brings a great deal of insight into this BB and he is the best researched on the science IMO.

This is only a BB, not a fight to the death between rival gangs.

https://www.proactiveinvestors.com.au/upload/SponsorFile/File/2018_03/1520590951_Scancell---3.pdf

Slide 17

This talks about 6 patients for the "safety run in" but doesn't say how long this will take.
From memory, I think the trial is at one centre only now.
Patients have to be suitable for both SCIB1 and KeyTruda.

For SCIB1 the patients had to be HLA type 2 which I believe covers 50% of people

https://clinicaltrials.gov/ct2/show/NCT01138410

For the combo trial, I believe this restriction is still in place event though Scancell have a version of SCIB1 that removes that restriction.

Well, its entirely in the hands of the FDA.
Once the FDA have approved the TriGrid2 device the trial can start.
CH has consistently said from the AGM onwards that the trial will start in H1.

He obviously knows more than us, but does he know for definite that the issue will be resolved in H1?

Shall we rollback today's BB and start again?
I am as guilty as anyone of posting badly today.

CRUK are paying for the SCIB2 combo trial.

I made the point very clumsily.
It must be hard for CRUK to sort out the logistics of so many concurrent trials.
Scancell only have to prepare for 2 trials. But I do think they have an excellent development director.

Morning Ruck

You are right, I don't have the facts.
Opinion only.
Probably due to the fact that they are running so many trials.
I apologise to CRUK staff.

I'm bored already.
Knowlesi or Tommy

Could you talk for 60 seconds without deviation, repetition or hesitation on the subject of Moditope?
Your time starts now.